Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (323)	8/4/2007 1:29:12 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

June 30, 2007--$36.7 million in combined cash, cash equivalents and marketable securities available-for-sale, compared to $43.1 million as of March 31, 2007. "The Company expects cash usage for the second half of 2007 to be lower than for the first half of 2007" "Gene Logic reported today that it has launched an effort to secure a development partner for its first proprietary drug candidate, GL1001, a compound acquired from Millennium Pharmaceuticals. Using an in vivo model, the Company has validated its hypothesis that this compound could be used for treatment of inflammatory bowel disease." yahoo.brand.edgar-online.com